Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States and internationally.
Slightly overvalued with imperfect balance sheet.
Share Price & News
How has Endo International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EO7's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: EO7 exceeded the German Pharmaceuticals industry which returned 6.8% over the past year.
Return vs Market: EO7 exceeded the German Market which returned 10.3% over the past year.
Price Volatility Vs. Market
How volatile is Endo International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Endo International undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EO7 (€2.69) is trading below our estimate of fair value (€15.53)
Significantly Below Fair Value: EO7 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EO7 is unprofitable, so we can't compare its PE Ratio to the XE Pharmaceuticals industry average.
PE vs Market: EO7 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EO7's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EO7 has negative assets, so we can't compare its PB Ratio to the DE Pharmaceuticals industry average.
How is Endo International forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EO7 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EO7 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EO7 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EO7's revenue is expected to decline over the next 3 years (-0.8% per year).
High Growth Revenue: EO7's revenue is forecast to decline over the next 3 years (-0.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EO7's Return on Equity is forecast to be high in 3 years time
How has Endo International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EO7 is currently unprofitable.
Growing Profit Margin: EO7 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EO7 is unprofitable, but has reduced losses over the past 5 years at a rate of 9% per year.
Accelerating Growth: Unable to compare EO7's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EO7 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.2%).
Return on Equity
High ROE: EO7's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Endo International's financial position?
Financial Position Analysis
Short Term Liabilities: EO7 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: EO7 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: EO7 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: EO7's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable EO7 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: EO7 is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 0.9% per year.
What is Endo International current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EO7's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EO7's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EO7's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EO7's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EO7's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Blaise Coleman (46 yo)
Mr. Blaise Coleman serves as President, Chief Executive Officer and Director at Endo International plc since March 06, 2020. Mr. Coleman was the Chief Financial Officer and Executive Vice President of Endo ...
CEO Compensation Analysis
Compensation vs Market: Blaise's total compensation ($USD3.57M) is above average for companies of similar size in the German market ($USD1.30M).
Compensation vs Earnings: Blaise's compensation has increased whilst the company is unprofitable.
|Executive VP & COO||3.75yrs||US$4.02m||0.15% |
|Executive VP & Chief Legal Officer||5.25yrs||US$3.43m||0.080% |
|Executive VP & President of Global Commercial Operations||3.67yrs||US$2.26m||0.038% |
|Executive VP & CFO||0.42yr||no data||0.014% |
|Senior VP||0.92yr||no data||0.015% |
|Senior VP of Information Technology & Chief Information Officer||3yrs||no data||no data|
|Senior Vice President of Investor Relations & Corporate Affairs||2yrs||no data||no data|
|Senior VP & Chief Compliance Officer||2.33yrs||no data||no data|
|Chief Human Resources Officer||1.58yrs||no data||no data|
|Executive Vice President of Global Quality and Compliance||3.75yrs||no data||no data|
|Executive Vice President of International Pharmaceuticals||3.75yrs||no data||0.022% |
Experienced Management: EO7's management team is considered experienced (2.7 years average tenure).
|Independent Director||0.50yr||no data||0.0058% |
|Independent Director||6.5yrs||US$315.00k||0.14% |
|Senior Independent Director||0.75yr||US$450.00k||0.094% |
|Independent Director||6.5yrs||US$320.00k||0.046% |
|Independent Director||6.08yrs||US$325.00k||0.041% |
|Independent Director||6.5yrs||US$320.00k||0.040% |
|Independent Non-Executive Director||0.083yr||no data||no data|
Experienced Board: EO7's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Endo International plc's company bio, employee growth, exchange listings and data sources
- Name: Endo International plc
- Ticker: EO7
- Exchange: DB
- Founded: 1920
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$728.517m
- Listing Market Cap: US$617.782m
- Shares outstanding: 229.82m
- Website: https://www.endo.com
Number of Employees
- Endo International plc
- Minerva House
- First Floor
- Co. Dublin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ENDP||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 2000|
|EO7||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2000|
|ENDP N||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jul 2000|
|0Y5F||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jul 2000|
Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, inclu ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/12 21:44|
|End of Day Share Price||2020/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.